Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Sintilimab||IBI308|Tyvyt||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Sintilimab||Phase I||Actionable||In a Phase I trial, Sintilimab (IBI308) demonstrated safety and preliminary efficacy, resulted in partial response in 18% (2/11) and stable disease in 18% (2/11) of patients with advanced solid tumors (J Clin Oncol 36, 2018 (suppl; abstr e15125)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03568539||Phase Ib/II||Sintilimab||IBI308 in Subjects With Advanced/Metastatic Solid Malignancies||Active, not recruiting|